Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice

Sally J. DeNardo, Zhengsheng Yao, Kit Lam, Aimin Song, Patricia A. Burke, Gary R. Mirick, Kathleen R. Lamborn, Robert T O'Donnell, Gerald L Denardo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Rapid blood and body clearances have hampered effective tumor targeting by small molecules. We used branched poly(ethylene glycol) (pegylated) polymers (Mr 40,000, Mr, 70,000, Mr, 100,000, and Mr, 150,000) conjugated to tumor-specific and control peptides to assess the effect of both molecular weight and tumor specificity on pharmacokinetics and biodistribution. Experimental Design: Pegylated specific lymphoma-binding peptide and control peptide (containing stereoisomers of proline and aspartate) were synthesized, radio-labeled with 111In, fractionated by size, and injected into Raji lymphoma-bearing athymic mice (4-6 mice/group). Pharmacokinetics were followed for 2 days to evaluate effects of specificity and molecular size on blood clearance, body clearance, and biodistribution. Results: As molecular size increased, blood and body clearances decreased (P < 0.001). The effect of molecular size on blood clearance was not altered by ligand binding specificity (P = 0.21), with t 1/2 ranging from 5.4 h (Mr 40,000) to 17.7 h (M r, 150,000). However, ligand specificity did alter body clearance, with pegylated control peptides clearing the body more slowly than pegylated specific peptides [P = 0.03; range, 19.1-91.3 h (specific peptides) versus 23.6-115.7 h (control peptides)]. At 24 h, there was more uptake of specific versus control pegylated peptides in tumor, liver, and marrow, but there was less uptake in kidneys, with a more pronounced difference for the higher molecular weight peptides (P < 0.01). Conclusions: These results demonstrate that the pharmacokinetics and biodistribution of peptides and resultant uptake in tumor and normal tissues can be altered by both molecular size and ligand specificity, with molecular size affecting pharmacokinetics and organ uptake in a predictable manner.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume9
Issue number10 II
StatePublished - Oct 1 2003

Fingerprint

Lymphoma
Pharmacokinetics
Peptides
Neoplasms
Ligands
Molecular Weight
Stereoisomerism
Ethylene Glycol
Radio
Proline
Nude Mice
Aspartic Acid
Polymers
Research Design
Bone Marrow
Kidney
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. / DeNardo, Sally J.; Yao, Zhengsheng; Lam, Kit; Song, Aimin; Burke, Patricia A.; Mirick, Gary R.; Lamborn, Kathleen R.; O'Donnell, Robert T; Denardo, Gerald L.

In: Clinical Cancer Research, Vol. 9, No. 10 II, 01.10.2003.

Research output: Contribution to journalArticle

DeNardo, Sally J. ; Yao, Zhengsheng ; Lam, Kit ; Song, Aimin ; Burke, Patricia A. ; Mirick, Gary R. ; Lamborn, Kathleen R. ; O'Donnell, Robert T ; Denardo, Gerald L. / Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 10 II.
@article{ebfc125ec2394a5ca29951be66314055,
title = "Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice",
abstract = "Purpose: Rapid blood and body clearances have hampered effective tumor targeting by small molecules. We used branched poly(ethylene glycol) (pegylated) polymers (Mr 40,000, Mr, 70,000, Mr, 100,000, and Mr, 150,000) conjugated to tumor-specific and control peptides to assess the effect of both molecular weight and tumor specificity on pharmacokinetics and biodistribution. Experimental Design: Pegylated specific lymphoma-binding peptide and control peptide (containing stereoisomers of proline and aspartate) were synthesized, radio-labeled with 111In, fractionated by size, and injected into Raji lymphoma-bearing athymic mice (4-6 mice/group). Pharmacokinetics were followed for 2 days to evaluate effects of specificity and molecular size on blood clearance, body clearance, and biodistribution. Results: As molecular size increased, blood and body clearances decreased (P < 0.001). The effect of molecular size on blood clearance was not altered by ligand binding specificity (P = 0.21), with t 1/2 ranging from 5.4 h (Mr 40,000) to 17.7 h (M r, 150,000). However, ligand specificity did alter body clearance, with pegylated control peptides clearing the body more slowly than pegylated specific peptides [P = 0.03; range, 19.1-91.3 h (specific peptides) versus 23.6-115.7 h (control peptides)]. At 24 h, there was more uptake of specific versus control pegylated peptides in tumor, liver, and marrow, but there was less uptake in kidneys, with a more pronounced difference for the higher molecular weight peptides (P < 0.01). Conclusions: These results demonstrate that the pharmacokinetics and biodistribution of peptides and resultant uptake in tumor and normal tissues can be altered by both molecular size and ligand specificity, with molecular size affecting pharmacokinetics and organ uptake in a predictable manner.",
author = "DeNardo, {Sally J.} and Zhengsheng Yao and Kit Lam and Aimin Song and Burke, {Patricia A.} and Mirick, {Gary R.} and Lamborn, {Kathleen R.} and O'Donnell, {Robert T} and Denardo, {Gerald L}",
year = "2003",
month = "10",
day = "1",
language = "English (US)",
volume = "9",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10 II",

}

TY - JOUR

T1 - Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice

AU - DeNardo, Sally J.

AU - Yao, Zhengsheng

AU - Lam, Kit

AU - Song, Aimin

AU - Burke, Patricia A.

AU - Mirick, Gary R.

AU - Lamborn, Kathleen R.

AU - O'Donnell, Robert T

AU - Denardo, Gerald L

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Purpose: Rapid blood and body clearances have hampered effective tumor targeting by small molecules. We used branched poly(ethylene glycol) (pegylated) polymers (Mr 40,000, Mr, 70,000, Mr, 100,000, and Mr, 150,000) conjugated to tumor-specific and control peptides to assess the effect of both molecular weight and tumor specificity on pharmacokinetics and biodistribution. Experimental Design: Pegylated specific lymphoma-binding peptide and control peptide (containing stereoisomers of proline and aspartate) were synthesized, radio-labeled with 111In, fractionated by size, and injected into Raji lymphoma-bearing athymic mice (4-6 mice/group). Pharmacokinetics were followed for 2 days to evaluate effects of specificity and molecular size on blood clearance, body clearance, and biodistribution. Results: As molecular size increased, blood and body clearances decreased (P < 0.001). The effect of molecular size on blood clearance was not altered by ligand binding specificity (P = 0.21), with t 1/2 ranging from 5.4 h (Mr 40,000) to 17.7 h (M r, 150,000). However, ligand specificity did alter body clearance, with pegylated control peptides clearing the body more slowly than pegylated specific peptides [P = 0.03; range, 19.1-91.3 h (specific peptides) versus 23.6-115.7 h (control peptides)]. At 24 h, there was more uptake of specific versus control pegylated peptides in tumor, liver, and marrow, but there was less uptake in kidneys, with a more pronounced difference for the higher molecular weight peptides (P < 0.01). Conclusions: These results demonstrate that the pharmacokinetics and biodistribution of peptides and resultant uptake in tumor and normal tissues can be altered by both molecular size and ligand specificity, with molecular size affecting pharmacokinetics and organ uptake in a predictable manner.

AB - Purpose: Rapid blood and body clearances have hampered effective tumor targeting by small molecules. We used branched poly(ethylene glycol) (pegylated) polymers (Mr 40,000, Mr, 70,000, Mr, 100,000, and Mr, 150,000) conjugated to tumor-specific and control peptides to assess the effect of both molecular weight and tumor specificity on pharmacokinetics and biodistribution. Experimental Design: Pegylated specific lymphoma-binding peptide and control peptide (containing stereoisomers of proline and aspartate) were synthesized, radio-labeled with 111In, fractionated by size, and injected into Raji lymphoma-bearing athymic mice (4-6 mice/group). Pharmacokinetics were followed for 2 days to evaluate effects of specificity and molecular size on blood clearance, body clearance, and biodistribution. Results: As molecular size increased, blood and body clearances decreased (P < 0.001). The effect of molecular size on blood clearance was not altered by ligand binding specificity (P = 0.21), with t 1/2 ranging from 5.4 h (Mr 40,000) to 17.7 h (M r, 150,000). However, ligand specificity did alter body clearance, with pegylated control peptides clearing the body more slowly than pegylated specific peptides [P = 0.03; range, 19.1-91.3 h (specific peptides) versus 23.6-115.7 h (control peptides)]. At 24 h, there was more uptake of specific versus control pegylated peptides in tumor, liver, and marrow, but there was less uptake in kidneys, with a more pronounced difference for the higher molecular weight peptides (P < 0.01). Conclusions: These results demonstrate that the pharmacokinetics and biodistribution of peptides and resultant uptake in tumor and normal tissues can be altered by both molecular size and ligand specificity, with molecular size affecting pharmacokinetics and organ uptake in a predictable manner.

UR - http://www.scopus.com/inward/record.url?scp=0141679553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141679553&partnerID=8YFLogxK

M3 - Article

C2 - 14506183

AN - SCOPUS:0141679553

VL - 9

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10 II

ER -